Reaserch Advance on Treatment Strategies for Relapsed/Refractory Hodgkin's Lymphoma--Review.
10.7534/j.issn.1009-2137.2020.01.058
- Author:
Dong-Cai JIN
1
;
Li ZHAO
2
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China.
2. Central Laboratory, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China,E-mail: zhaoli@lzu.edu.cn.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):343-349
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Although the majority of patients with Hodgkin's lymphoma (HL) can be cured with upfront treatment, but a fraction of patients with advanced disease will experience refractory or recurrence leading to poor prognosis. How to treat these patients is the focus of current research. High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (HDCT/auto-HSCT) is the standard salvage approach for patients with HL who have relapsed/refractory disease after frontline chemotherapy. In recent years, salvage therapy incorporating newer drugs, such as targeted drugs Brentuximab vedotin (BV), checkpoint inhibitors Nivolumab and Pembrolizumab have shown some efficacy in early clinical trials. In addition, Ibrutinib, Everolimus and other drugs have also shown a promising perspective. In this review, the advances in the therapy strategies for relapsed/refractory HL are discussed and summarized.
